Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pulmatrix Inc (PULM)

Pulmatrix Inc (PULM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets PR Newswire - Thu Oct 16, 7:05AM CDT

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets PR Newswire - Wed Aug 6, 7:05AM CDT

Proposed merger anticipated to close in 2025

PULM : 4.10 (-5.75%)
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire - Tue Jul 11, 2023

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 4.10 (-5.75%)
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society PR Newswire - Thu Jun 15, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention PR Newswire - Wed May 24, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Fri May 12, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Supports World Asthma Day 2023 PR Newswire - Tue May 2, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)

Barchart Exclusives

This High-Yield Dividend Stock Trades at a Third of Its Record Highs: Is It a Buy for 2026? Barchart - Tue Dec 16, 6:30PM CST
Nike stock has a dividend yield of 2.4% and trades at a third of its 2021 highs. The stock could, however, see upside next year as it progresses on the turnaround strategy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot